RESUMEN
The grasshopper genus Mongolotettix Rehn, 1928 obtains 17 species distributed from the Far Eastern Asian countries, including China, Japan, Korea, Mongolia, and Russia [Bolvar, 1898; Uvarov, 1914; Caudell, 1921; Chogsomzhav, 1974; Li et Lian, 1994; Wan, Ren et Zhang, 1998; Xie et Li, 2000; Kim et Kim 2005; Shi et al, 2016; Shi et al, 2017; Yin et al, 2017; Zheng et al, 2017; Chen et al, 2018; Zhang et al, 2020; Cigliano et al, 2022, Shen et al, 2022]. In the present paper, we describe a new species of the genus from Jiangxi, China. Type specimens are deposited in the Shanghai Entomological Museum, Chinese Academy of Sciences, Shanghai, 200032, China.
Asunto(s)
Saltamontes , Ortópteros , Animales , China , Estructuras Animales , Tamaño Corporal , Tamaño de los Órganos , Distribución AnimalRESUMEN
@#Objective To evaluate the effects of various polysorbates(PS)on the stability of different types of monoclonal antibody(mAb)drugs.Methods Three types of monoclonal antibodies mAbA(IgG1 proantibody drug),mAbB(IgG1 mAb)and mAbC(IgG1 mAb with Fc N297A mutation)were used as model proteins,and different kinds or contents of PS were added into the mAb formulations respectively to investigate the influencing factors.The effects of PS on the stability of mAb drugs were evaluated comprehensively by detecting the changes of quality attributes,such as protein aggregates and insoluble particles.Results PS20 and PS80 showed no significant difference in inhibiting the formation of aggregates and charge variants in the three mAbs(P>0.05),while the addition of PS80 in mAbB and PS20 in mAbC significantly inhibited the increase of insoluble particles respectively(P<0.05);The content of PS20 showed a significant effect on the detection indexes of charge variants and insoluble particles in mAbC(P<0.05).Conclusion Different types of mAbs have different sensitivities to various kinds and contents of PS.Therefore,when designing the formulation of mAbs,it is necessary to select appropriate kinds and contents of PS to further improve the stability of mAb drugs.